Cancer Gene Therapy

Antisense ODNs Target RI(alpha) Subunit Protein Kinase A

Published in Cancer Weekly, January 11th, 2000

by Michelle Marble -- Oral administration of a mixed-backbone antisense oligonucleotide (ODN) targeted to the RI(alpha) subunit of protein kinase A has antitumor activity.

Research has demonstrated the overexpression of the RI(alpha) subunit of cAMP-dependent protein kinase (PKA) in several human cancers. As such, PKA has been suggested as a potential target for anticancer strategies.

Hui Wang and colleagues from the University of Alabama, and Hybridon, Inc., Massachusetts, evaluated an anti-PKA antisense oligonucleotide (mixed backbone oligonucleotide [MBO]) as a therapeutic approach to human cancer. Data from their study was published in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry